Ameliorating effect of lipo-ATRA treatment on the expression of TIG3 and its suppressing effect on PPARγ gene expression in lung cancer animal model

This study aimed to find out the molecular therapeutic effect of lipo-ATRA on tumour suppressor TIG3 and cell proliferative biomarker PPARγ in B (a) P-induced lung cancer model. In RT-PCR study, ATRA- and lipo-ATRA-treated mice samples showed relatively higher TIG3 expression and decreased PPARγ exp...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and cellular biochemistry 2019-10, Vol.460 (1-2), p.105-112
Main Authors: Ravichandran, Ragavi, Viswanathan, S., Berlin Grace, V. M., Bonati, Lucia, Narayanan, Jini
Format: Article
Language:English
Subjects:
Animal models
Animals
Biochemistry
Biomarkers
Biomedical and Life Sciences
Cardiology
Disease Models, Animal
Gene expression
Gene Expression Regulation, Neoplastic - drug effects
Life Sciences
Liposomes
Lung cancer
Lung Neoplasms - genetics
Lung Neoplasms - pathology
Male
Medical Biochemistry
Mice
Oncology
Peroxisome proliferator-activated receptors
Polymerase chain reaction
PPAR gamma - genetics
PPAR gamma - metabolism
Receptors, Retinoic Acid - genetics
Receptors, Retinoic Acid - metabolism
Tretinoin - pharmacology
Tumor Suppressor Proteins - genetics
Tumor Suppressor Proteins - metabolism
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This study aimed to find out the molecular therapeutic effect of lipo-ATRA on tumour suppressor TIG3 and cell proliferative biomarker PPARγ in B (a) P-induced lung cancer model. In RT-PCR study, ATRA- and lipo-ATRA-treated mice samples showed relatively higher TIG3 expression and decreased PPARγ expression (Band density) than cancer control. Among treatments, lipo-ATRA showed vital effect than free ATRA by enhancing TIG3 and decreasing PPARγ. The qPCR results also showed significant ( p  ≤ 0.05) difference in both TIG3 and PPAR (RQ values of TIG3, lipo-ATRA 23.85 ± 1.29; free ATRA 10.43 ± 1.81 and for PPARγ, lipo-ATRA 4.707 ± 1.21; free ATRA 15.78 ± 2.34). From this, we conclude that liposomal ATRA formulation is most preferable for prolonged delivery of ATRA at targeted site to favour molecular action. It implies that the therapeutic effect of lipo-ATRA in lung cancer was exhibited by ameliorating the TIG3 expression and by suppressing the expression of PPARγ.
ISSN:0300-8177
1573-4919
DOI:10.1007/s11010-019-03574-z